12.65
price down icon3.21%   -0.42
after-market 시간 외 거래: 12.65
loading

Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스

pulisher
11:14 AM

(VRDN) Trading Report - news.stocktradersdaily.com

11:14 AM
pulisher
Apr 02, 2025

Teacher Retirement System of Texas Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Financial Analysis: Viridian Therapeutics (NASDAQ:VRDN) versus ACI Global (OTCMKTS:ACGJ) - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Quantbot Technologies LP Invests $164,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Swiss National Bank - Defense World

Mar 28, 2025
pulisher
Mar 25, 2025

Raymond James Financial Inc. Makes New $6.02 Million Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Where are the Opportunities in (VRDN) - news.stocktradersdaily.com

Mar 24, 2025
pulisher
Mar 22, 2025

Charles Schwab Investment Management Inc. Raises Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

AlphaQuest LLC Acquires 1,519 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Commit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using Options - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Bank of New York Mellon Corp - Defense World

Mar 19, 2025
pulisher
Mar 16, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Arizona State Retirement System - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 15, 2025
pulisher
Mar 15, 2025

410,440 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Victory Capital Management Inc. - Defense World

Mar 15, 2025
pulisher
Mar 12, 2025

Viridian Therapeutics at Leerink’s Conference: Progress in TED Treatments By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 10, 2025

Viridian Therapeutics appoints new director, sees board resignation By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Viridian Therapeutics Announces Inducement Stock Option Grants - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Viridian Therapeutics appoints new director, sees board resignation - Investing.com India

Mar 10, 2025
pulisher
Mar 06, 2025

What is B. Riley’s Forecast for VRDN Q1 Earnings? - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Principal Financial Group Inc. Has $3.42 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

What is B. Riley’s Estimate for VRDN Q2 Earnings? - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus.com

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics inks new $300M sales agreement By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics Terminates Prior $175 Million Sale Agreement -March 04, 2025 at 06:36 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics Enters New $300M Sale Agreement - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics inks new $300M sales agreement - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Rhumbline Advisers Has $1.92 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges - TipRanks

Mar 04, 2025
pulisher
Mar 03, 2025

Viridian Therapeutics, Inc.\DE SEC 10-K Report - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Q1 EPS Estimates for Viridian Therapeutics Raised by Wedbush - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

How to Take Advantage of moves in (VRDN) - Stock Traders Daily

Mar 02, 2025
pulisher
Mar 02, 2025

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window - Seeking Alpha

Mar 02, 2025
pulisher
Mar 02, 2025

FY2027 EPS Forecast for Viridian Therapeutics Cut by Analyst - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Viridian Therapeutics (NASDAQ:VRDN) Posts Earnings Results, Beats Expectations By $0.24 EPS - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

RBC Capital Adjusts Viridian Therapeutics Price Target to $46 From $47, Maintains OutperformSpeculative Risk Rating - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Viridian Therapeutics: Promising Market Position and Growth Prospects Justify Buy Rating - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Viridian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK

Feb 28, 2025
pulisher
Feb 28, 2025

Viridian Therapeutics Reports Strong Progress and Financials - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics reports Q4 EPS (81c), consensus ($1.04) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics Positioned for Market Leadership with Strategic Advancements and Competitive Edge - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

VRDNViridian Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics: Strong TED Trial Results and Promising Pipeline Drive Buy Rating - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics' Q4 Net Loss Narrows, Revenue Flat -February 27, 2025 at 09:27 am EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Earnings Flash (VRDN) Viridian Therapeutics Posts Q4 Revenue $72,000 -February 27, 2025 at 07:20 am EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Earnings Flash (VRDN) Viridian Therapeutics Posts Q4 Net Loss $0.81 a Share, vs. FactSet Est of $1.05 Loss - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire

Feb 27, 2025
pulisher
Feb 25, 2025

Viridian Therapeutics Becomes Oversold (VRDN) - Nasdaq

Feb 25, 2025
pulisher
Feb 23, 2025

Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Tuesday - Defense World

Feb 23, 2025
pulisher
Feb 23, 2025

Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $35.70 - MarketBeat

Feb 23, 2025
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
자본화:     |  볼륨(24시간):